-
CSR Summary Not yet available
-
NCT02165397
-
Primary Citation Trial has yet to be published
-
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameIbrutinibProduct NameIMBRUVICA®Therapeutic AreaCancers and Other NeoplasmsEnrollment181% FemaleN/A% WhiteN/A
Product ClassKinase InhibitorsSponsor Protocol NumberPCYC-1127-CAData PartnerJohnson & JohnsonCondition StudiedNeoplasmsMean/Median Age (Years)N/A
Supporting Documentation
- Collected Datasets Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available